Evaluation of combined exposure of sevoflurane and anti cancer drugs

2018 Fiscal Year Final Research Report

• Project/Area Number: 15K15569
• Research Category: Grant-in-Aid for Challenging Exploratory Research
• Allocation Type: Multi-year Fund
• Research Field: Anesthesiology
• Research Institution: Nagoya University
• Principal Investigator: Hirai Takahiro 名古屋大学, 医学部附属病院, 病院助教 (00612798)
• Research Collaborator: Nishiwaki Kimitoshi
• Project Period (FY): 2015-04-01 – 2019-03-31
• Keywords: セボフルラン / がん細胞株

Outline of Final Research Achievements

Some of anticancer drugs which mimic DNA component were taken to cancer cell when the cells were in cell cycle progression. To date we have investigated some of cancer cells were slightly increased cell population accompanied with DNA replication. Whereas our continuous study with this theme, we found that sevoflurane exposed cells that cultured with anti-cancer drug for 24 hours did not show significant reduction compared with anti cancer single treatment control.

Free Research Field

麻酔

Academic Significance and Societal Importance of the Research Achievements

本研究でセボフルラン暴露後にがん細胞株がDNA合成期を増加させたことを利用し、セボフルランと抗癌剤の併用培養によって抗がん剤の薬剤感受性を高めると考えこれを検証した。しかし、予想したような結果は得られなかった。また一部の抗がん剤は暴露が原因とする細胞死抵抗性を高めたことから、より効果的な添加方法など検討が必要である。期待した成果は得られなかったが、増加するがん患者さんの治療に考慮した麻酔薬の基礎データ提供の足掛かりになると考える。